[Special Stock] Samsung Biologics Turns Down After 8 Trading Days

[Asia Economy Reporter Song Hwajeong] Samsung Biologics' winning streak has stopped after 8 trading days. It has fallen back below the 900,000 won level.

As of 9:24 a.m. on the 17th, Samsung Biologics was trading at 892,000 won, down 56,000 won (5.91%) from the previous day. The recent sharp rise appears to have become a burden, turning the stock bearish. Samsung Biologics had risen for 7 consecutive trading days from the 6th to the 14th. In particular, on the 14th, it surged more than 9%, reaching 948,000 won and setting a new all-time high.

Expectations for Moderna's COVID-19 vaccine contract manufacturing had driven the stock price up until now. On the 14th, Samsung Biologics announced regarding the contract manufacturing of Moderna's COVID-19 vaccine, "There is currently no confirmation, so verification is not possible," and stated, "We will re-disclose at a time when confirmation is possible or within one month." By expressing the intention to re-disclose later, the market interpreted that negotiations are ongoing. Huh Hyemin, a researcher at Kiwoom Securities, said, "The future stock price direction depends on the contract signing and disclosure of contract terms, but due to confidentiality with the client, the company may not disclose the announcement or detailed amounts."

This content was produced with the assistance of AI translation services.